Monoclonal Antibodies for Non-small Cell Lung Cancer Market Research Report from 2025 forecast to 2031, by Manufacturers, Regions, Type and Application

The global Monoclonal Antibodies for Non-small Cell Lung Cancer market size was valued at USD 12020 million in 2024 and is forecast to a readjusted size of USD 24920 million by 2031 with a CAGR of 10.9% during review period.

Non-Monoclonal Antibodies for Non-small Cell Lung Cancer are a class of biological agents targeting specific targets of non-small cell lung cancer (NSCLC), aiming to enhance the body's immune response by targeting specific antigens or immune checkpoints on the surface of cancer cells, thereby inhibiting tumor growth and metastasis. These monoclonal antibodies can be used to treat advanced or recurrent NSCLC, often in combination with chemotherapy or other immunotherapies, to increase treatment efficacy and improve patient survival.

This report is a detailed and comprehensive analysis for global Monoclonal Antibodies for Non-small Cell Lung Cancer market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.

Key Features:

Global Monoclonal Antibodies for Non-small Cell Lung Cancer market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Monoclonal Antibodies for Non-small Cell Lung Cancer market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Monoclonal Antibodies for Non-small Cell Lung Cancer market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Monoclonal Antibodies for Non-small Cell Lung Cancer market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2020-2025

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Monoclonal Antibodies for Non-small Cell Lung Cancer
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace

This report profiles key players in the global Monoclonal Antibodies for Non-small Cell Lung Cancer market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

   Roche Holding AG
   Bristol Myers Squibb Co.
   Elea Spa
   Eli Lilly & Co.
   Merck & Co., Inc.
   AstraZeneca PLC
   Regeneron Pharmaceuticals, Inc.
   Henlius Biopharma Co., Ltd
   Jiangsu Hengrui Medicine Co., Ltd
   Innovent Biologics Co., Ltd
   Junshi Biosciences Co., Ltd
   BeiGene, Ltd
   Akeso, Inc

   5 mg/mL
   10 mg/mL
   25 mg/mL
   50 mg/mL

   Hospitals
   Clinic
   Others

North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

Chapter 1, to describe Monoclonal Antibodies for Non-small Cell Lung Cancer product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Monoclonal Antibodies for Non-small Cell Lung Cancer, with price, sales quantity, revenue, and global market share of Monoclonal Antibodies for Non-small Cell Lung Cancer from 2020 to 2025.
Chapter 3, the Monoclonal Antibodies for Non-small Cell Lung Cancer competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Monoclonal Antibodies for Non-small Cell Lung Cancer breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Monoclonal Antibodies for Non-small Cell Lung Cancer market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Monoclonal Antibodies for Non-small Cell Lung Cancer.
Chapter 14 and 15, to describe Monoclonal Antibodies for Non-small Cell Lung Cancer sales channel, distributors, customers, research findings and conclusion.

1 Market Overview

1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value by Type: 2020 Versus 2024 Versus 2031
1.3.2 5 mg/mL
1.3.3 10 mg/mL
1.3.4 25 mg/mL
1.3.5 50 mg/mL
1.4 Market Analysis by Application
1.4.1 Overview: Global Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value by Application: 2020 Versus 2024 Versus 2031
1.4.2 Hospitals
1.4.3 Clinic
1.4.4 Others
1.5 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size & Forecast
1.5.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value (2020 & 2024 & 2031)
1.5.2 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity (2020-2031)
1.5.3 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Average Price (2020-2031)

2 Manufacturers Profiles

2.1 Roche Holding AG
2.1.1 Roche Holding AG Details
2.1.2 Roche Holding AG Major Business
2.1.3 Roche Holding AG Monoclonal Antibodies for Non-small Cell Lung Cancer Product and Services
2.1.4 Roche Holding AG Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.1.5 Roche Holding AG Recent Developments/Updates
2.2 Bristol Myers Squibb Co.
2.2.1 Bristol Myers Squibb Co. Details
2.2.2 Bristol Myers Squibb Co. Major Business
2.2.3 Bristol Myers Squibb Co. Monoclonal Antibodies for Non-small Cell Lung Cancer Product and Services
2.2.4 Bristol Myers Squibb Co. Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.2.5 Bristol Myers Squibb Co. Recent Developments/Updates
2.3 Elea Spa
2.3.1 Elea Spa Details
2.3.2 Elea Spa Major Business
2.3.3 Elea Spa Monoclonal Antibodies for Non-small Cell Lung Cancer Product and Services
2.3.4 Elea Spa Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.3.5 Elea Spa Recent Developments/Updates
2.4 Eli Lilly & Co.
2.4.1 Eli Lilly & Co. Details
2.4.2 Eli Lilly & Co. Major Business
2.4.3 Eli Lilly & Co. Monoclonal Antibodies for Non-small Cell Lung Cancer Product and Services
2.4.4 Eli Lilly & Co. Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.4.5 Eli Lilly & Co. Recent Developments/Updates
2.5 Merck & Co., Inc.
2.5.1 Merck & Co., Inc. Details
2.5.2 Merck & Co., Inc. Major Business
2.5.3 Merck & Co., Inc. Monoclonal Antibodies for Non-small Cell Lung Cancer Product and Services
2.5.4 Merck & Co., Inc. Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.5.5 Merck & Co., Inc. Recent Developments/Updates
2.6 AstraZeneca PLC
2.6.1 AstraZeneca PLC Details
2.6.2 AstraZeneca PLC Major Business
2.6.3 AstraZeneca PLC Monoclonal Antibodies for Non-small Cell Lung Cancer Product and Services
2.6.4 AstraZeneca PLC Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.6.5 AstraZeneca PLC Recent Developments/Updates
2.7 Regeneron Pharmaceuticals, Inc.
2.7.1 Regeneron Pharmaceuticals, Inc. Details
2.7.2 Regeneron Pharmaceuticals, Inc. Major Business
2.7.3 Regeneron Pharmaceuticals, Inc. Monoclonal Antibodies for Non-small Cell Lung Cancer Product and Services
2.7.4 Regeneron Pharmaceuticals, Inc. Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.7.5 Regeneron Pharmaceuticals, Inc. Recent Developments/Updates
2.8 Henlius Biopharma Co., Ltd
2.8.1 Henlius Biopharma Co., Ltd Details
2.8.2 Henlius Biopharma Co., Ltd Major Business
2.8.3 Henlius Biopharma Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product and Services
2.8.4 Henlius Biopharma Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.8.5 Henlius Biopharma Co., Ltd Recent Developments/Updates
2.9 Jiangsu Hengrui Medicine Co., Ltd
2.9.1 Jiangsu Hengrui Medicine Co., Ltd Details
2.9.2 Jiangsu Hengrui Medicine Co., Ltd Major Business
2.9.3 Jiangsu Hengrui Medicine Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product and Services
2.9.4 Jiangsu Hengrui Medicine Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.9.5 Jiangsu Hengrui Medicine Co., Ltd Recent Developments/Updates
2.10 Innovent Biologics Co., Ltd
2.10.1 Innovent Biologics Co., Ltd Details
2.10.2 Innovent Biologics Co., Ltd Major Business
2.10.3 Innovent Biologics Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product and Services
2.10.4 Innovent Biologics Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.10.5 Innovent Biologics Co., Ltd Recent Developments/Updates
2.11 Junshi Biosciences Co., Ltd
2.11.1 Junshi Biosciences Co., Ltd Details
2.11.2 Junshi Biosciences Co., Ltd Major Business
2.11.3 Junshi Biosciences Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product and Services
2.11.4 Junshi Biosciences Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.11.5 Junshi Biosciences Co., Ltd Recent Developments/Updates
2.12 BeiGene, Ltd
2.12.1 BeiGene, Ltd Details
2.12.2 BeiGene, Ltd Major Business
2.12.3 BeiGene, Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product and Services
2.12.4 BeiGene, Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.12.5 BeiGene, Ltd Recent Developments/Updates
2.13 Akeso, Inc
2.13.1 Akeso, Inc Details
2.13.2 Akeso, Inc Major Business
2.13.3 Akeso, Inc Monoclonal Antibodies for Non-small Cell Lung Cancer Product and Services
2.13.4 Akeso, Inc Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.13.5 Akeso, Inc Recent Developments/Updates

3 Competitive Environment: Monoclonal Antibodies for Non-small Cell Lung Cancer by Manufacturer

3.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity by Manufacturer (2020-2025)
3.2 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Manufacturer (2020-2025)
3.3 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Average Price by Manufacturer (2020-2025)
3.4 Market Share Analysis (2024)
3.4.1 Producer Shipments of Monoclonal Antibodies for Non-small Cell Lung Cancer by Manufacturer Revenue ($MM) and Market Share (%): 2024
3.4.2 Top 3 Monoclonal Antibodies for Non-small Cell Lung Cancer Manufacturer Market Share in 2024
3.4.3 Top 6 Monoclonal Antibodies for Non-small Cell Lung Cancer Manufacturer Market Share in 2024
3.5 Monoclonal Antibodies for Non-small Cell Lung Cancer Market: Overall Company Footprint Analysis
3.5.1 Monoclonal Antibodies for Non-small Cell Lung Cancer Market: Region Footprint
3.5.2 Monoclonal Antibodies for Non-small Cell Lung Cancer Market: Company Product Type Footprint
3.5.3 Monoclonal Antibodies for Non-small Cell Lung Cancer Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

4.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size by Region
4.1.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity by Region (2020-2031)
4.1.2 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value by Region (2020-2031)
4.1.3 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Average Price by Region (2020-2031)
4.2 North America Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value (2020-2031)
4.3 Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value (2020-2031)
4.4 Asia-Pacific Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value (2020-2031)
4.5 South America Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value (2020-2031)
4.6 Middle East & Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value (2020-2031)

5 Market Segment by Type

5.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity by Type (2020-2031)
5.2 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value by Type (2020-2031)
5.3 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Average Price by Type (2020-2031)

6 Market Segment by Application

6.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity by Application (2020-2031)
6.2 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value by Application (2020-2031)
6.3 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Average Price by Application (2020-2031)

7 North America

7.1 North America Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity by Type (2020-2031)
7.2 North America Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity by Application (2020-2031)
7.3 North America Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size by Country
7.3.1 North America Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity by Country (2020-2031)
7.3.2 North America Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value by Country (2020-2031)
7.3.3 United States Market Size and Forecast (2020-2031)
7.3.4 Canada Market Size and Forecast (2020-2031)
7.3.5 Mexico Market Size and Forecast (2020-2031)

8 Europe

8.1 Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity by Type (2020-2031)
8.2 Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity by Application (2020-2031)
8.3 Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size by Country
8.3.1 Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity by Country (2020-2031)
8.3.2 Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value by Country (2020-2031)
8.3.3 Germany Market Size and Forecast (2020-2031)
8.3.4 France Market Size and Forecast (2020-2031)
8.3.5 United Kingdom Market Size and Forecast (2020-2031)
8.3.6 Russia Market Size and Forecast (2020-2031)
8.3.7 Italy Market Size and Forecast (2020-2031)

9 Asia-Pacific

9.1 Asia-Pacific Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity by Type (2020-2031)
9.2 Asia-Pacific Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity by Application (2020-2031)
9.3 Asia-Pacific Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size by Region
9.3.1 Asia-Pacific Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity by Region (2020-2031)
9.3.2 Asia-Pacific Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value by Region (2020-2031)
9.3.3 China Market Size and Forecast (2020-2031)
9.3.4 Japan Market Size and Forecast (2020-2031)
9.3.5 South Korea Market Size and Forecast (2020-2031)
9.3.6 India Market Size and Forecast (2020-2031)
9.3.7 Southeast Asia Market Size and Forecast (2020-2031)
9.3.8 Australia Market Size and Forecast (2020-2031)

10 South America

10.1 South America Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity by Type (2020-2031)
10.2 South America Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity by Application (2020-2031)
10.3 South America Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size by Country
10.3.1 South America Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity by Country (2020-2031)
10.3.2 South America Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value by Country (2020-2031)
10.3.3 Brazil Market Size and Forecast (2020-2031)
10.3.4 Argentina Market Size and Forecast (2020-2031)

11 Middle East & Africa

11.1 Middle East & Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity by Type (2020-2031)
11.2 Middle East & Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity by Application (2020-2031)
11.3 Middle East & Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size by Country
11.3.1 Middle East & Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity by Country (2020-2031)
11.3.2 Middle East & Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value by Country (2020-2031)
11.3.3 Turkey Market Size and Forecast (2020-2031)
11.3.4 Egypt Market Size and Forecast (2020-2031)
11.3.5 Saudi Arabia Market Size and Forecast (2020-2031)
11.3.6 South Africa Market Size and Forecast (2020-2031)

12 Market Dynamics

12.1 Monoclonal Antibodies for Non-small Cell Lung Cancer Market Drivers
12.2 Monoclonal Antibodies for Non-small Cell Lung Cancer Market Restraints
12.3 Monoclonal Antibodies for Non-small Cell Lung Cancer Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

13.1 Raw Material of Monoclonal Antibodies for Non-small Cell Lung Cancer and Key Manufacturers
13.2 Manufacturing Costs Percentage of Monoclonal Antibodies for Non-small Cell Lung Cancer
13.3 Monoclonal Antibodies for Non-small Cell Lung Cancer Production Process
13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Monoclonal Antibodies for Non-small Cell Lung Cancer Typical Distributors
14.3 Monoclonal Antibodies for Non-small Cell Lung Cancer Typical Customers

15 Research Findings and Conclusion

16 Appendix

16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer

List of Tables

Table 1. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value by Type, (USD Million), 2020 & 2024 & 2031
Table 2. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value by Application, (USD Million), 2020 & 2024 & 2031
Table 3. Roche Holding AG Basic Information, Manufacturing Base and Competitors
Table 4. Roche Holding AG Major Business
Table 5. Roche Holding AG Monoclonal Antibodies for Non-small Cell Lung Cancer Product and Services
Table 6. Roche Holding AG Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 7. Roche Holding AG Recent Developments/Updates
Table 8. Bristol Myers Squibb Co. Basic Information, Manufacturing Base and Competitors
Table 9. Bristol Myers Squibb Co. Major Business
Table 10. Bristol Myers Squibb Co. Monoclonal Antibodies for Non-small Cell Lung Cancer Product and Services
Table 11. Bristol Myers Squibb Co. Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 12. Bristol Myers Squibb Co. Recent Developments/Updates
Table 13. Elea Spa Basic Information, Manufacturing Base and Competitors
Table 14. Elea Spa Major Business
Table 15. Elea Spa Monoclonal Antibodies for Non-small Cell Lung Cancer Product and Services
Table 16. Elea Spa Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 17. Elea Spa Recent Developments/Updates
Table 18. Eli Lilly & Co. Basic Information, Manufacturing Base and Competitors
Table 19. Eli Lilly & Co. Major Business
Table 20. Eli Lilly & Co. Monoclonal Antibodies for Non-small Cell Lung Cancer Product and Services
Table 21. Eli Lilly & Co. Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 22. Eli Lilly & Co. Recent Developments/Updates
Table 23. Merck & Co., Inc. Basic Information, Manufacturing Base and Competitors
Table 24. Merck & Co., Inc. Major Business
Table 25. Merck & Co., Inc. Monoclonal Antibodies for Non-small Cell Lung Cancer Product and Services
Table 26. Merck & Co., Inc. Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 27. Merck & Co., Inc. Recent Developments/Updates
Table 28. AstraZeneca PLC Basic Information, Manufacturing Base and Competitors
Table 29. AstraZeneca PLC Major Business
Table 30. AstraZeneca PLC Monoclonal Antibodies for Non-small Cell Lung Cancer Product and Services
Table 31. AstraZeneca PLC Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 32. AstraZeneca PLC Recent Developments/Updates
Table 33. Regeneron Pharmaceuticals, Inc. Basic Information, Manufacturing Base and Competitors
Table 34. Regeneron Pharmaceuticals, Inc. Major Business
Table 35. Regeneron Pharmaceuticals, Inc. Monoclonal Antibodies for Non-small Cell Lung Cancer Product and Services
Table 36. Regeneron Pharmaceuticals, Inc. Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 37. Regeneron Pharmaceuticals, Inc. Recent Developments/Updates
Table 38. Henlius Biopharma Co., Ltd Basic Information, Manufacturing Base and Competitors
Table 39. Henlius Biopharma Co., Ltd Major Business
Table 40. Henlius Biopharma Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product and Services
Table 41. Henlius Biopharma Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 42. Henlius Biopharma Co., Ltd Recent Developments/Updates
Table 43. Jiangsu Hengrui Medicine Co., Ltd Basic Information, Manufacturing Base and Competitors
Table 44. Jiangsu Hengrui Medicine Co., Ltd Major Business
Table 45. Jiangsu Hengrui Medicine Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product and Services
Table 46. Jiangsu Hengrui Medicine Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 47. Jiangsu Hengrui Medicine Co., Ltd Recent Developments/Updates
Table 48. Innovent Biologics Co., Ltd Basic Information, Manufacturing Base and Competitors
Table 49. Innovent Biologics Co., Ltd Major Business
Table 50. Innovent Biologics Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product and Services
Table 51. Innovent Biologics Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 52. Innovent Biologics Co., Ltd Recent Developments/Updates
Table 53. Junshi Biosciences Co., Ltd Basic Information, Manufacturing Base and Competitors
Table 54. Junshi Biosciences Co., Ltd Major Business
Table 55. Junshi Biosciences Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product and Services
Table 56. Junshi Biosciences Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 57. Junshi Biosciences Co., Ltd Recent Developments/Updates
Table 58. BeiGene, Ltd Basic Information, Manufacturing Base and Competitors
Table 59. BeiGene, Ltd Major Business
Table 60. BeiGene, Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product and Services
Table 61. BeiGene, Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 62. BeiGene, Ltd Recent Developments/Updates
Table 63. Akeso, Inc Basic Information, Manufacturing Base and Competitors
Table 64. Akeso, Inc Major Business
Table 65. Akeso, Inc Monoclonal Antibodies for Non-small Cell Lung Cancer Product and Services
Table 66. Akeso, Inc Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 67. Akeso, Inc Recent Developments/Updates
Table 68. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity by Manufacturer (2020-2025) & (K Units)
Table 69. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Manufacturer (2020-2025) & (USD Million)
Table 70. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Average Price by Manufacturer (2020-2025) & (US$/Unit)
Table 71. Market Position of Manufacturers in Monoclonal Antibodies for Non-small Cell Lung Cancer, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2024
Table 72. Head Office and Monoclonal Antibodies for Non-small Cell Lung Cancer Production Site of Key Manufacturer
Table 73. Monoclonal Antibodies for Non-small Cell Lung Cancer Market: Company Product Type Footprint
Table 74. Monoclonal Antibodies for Non-small Cell Lung Cancer Market: Company Product Application Footprint
Table 75. Monoclonal Antibodies for Non-small Cell Lung Cancer New Market Entrants and Barriers to Market Entry
Table 76. Monoclonal Antibodies for Non-small Cell Lung Cancer Mergers, Acquisition, Agreements, and Collaborations
Table 77. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value by Region (2020-2024-2031) & (USD Million) & CAGR
Table 78. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity by Region (2020-2025) & (K Units)
Table 79. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity by Region (2026-2031) & (K Units)
Table 80. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value by Region (2020-2025) & (USD Million)
Table 81. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value by Region (2026-2031) & (USD Million)
Table 82. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Average Price by Region (2020-2025) & (US$/Unit)
Table 83. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Average Price by Region (2026-2031) & (US$/Unit)
Table 84. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity by Type (2020-2025) & (K Units)
Table 85. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity by Type (2026-2031) & (K Units)
Table 86. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value by Type (2020-2025) & (USD Million)
Table 87. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value by Type (2026-2031) & (USD Million)
Table 88. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Average Price by Type (2020-2025) & (US$/Unit)
Table 89. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Average Price by Type (2026-2031) & (US$/Unit)
Table 90. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity by Application (2020-2025) & (K Units)
Table 91. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity by Application (2026-2031) & (K Units)
Table 92. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value by Application (2020-2025) & (USD Million)
Table 93. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value by Application (2026-2031) & (USD Million)
Table 94. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Average Price by Application (2020-2025) & (US$/Unit)
Table 95. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Average Price by Application (2026-2031) & (US$/Unit)
Table 96. North America Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity by Type (2020-2025) & (K Units)
Table 97. North America Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity by Type (2026-2031) & (K Units)
Table 98. North America Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity by Application (2020-2025) & (K Units)
Table 99. North America Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity by Application (2026-2031) & (K Units)
Table 100. North America Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity by Country (2020-2025) & (K Units)
Table 101. North America Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity by Country (2026-2031) & (K Units)
Table 102. North America Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value by Country (2020-2025) & (USD Million)
Table 103. North America Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value by Country (2026-2031) & (USD Million)
Table 104. Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity by Type (2020-2025) & (K Units)
Table 105. Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity by Type (2026-2031) & (K Units)
Table 106. Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity by Application (2020-2025) & (K Units)
Table 107. Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity by Application (2026-2031) & (K Units)
Table 108. Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity by Country (2020-2025) & (K Units)
Table 109. Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity by Country (2026-2031) & (K Units)
Table 110. Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value by Country (2020-2025) & (USD Million)
Table 111. Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value by Country (2026-2031) & (USD Million)
Table 112. Asia-Pacific Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity by Type (2020-2025) & (K Units)
Table 113. Asia-Pacific Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity by Type (2026-2031) & (K Units)
Table 114. Asia-Pacific Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity by Application (2020-2025) & (K Units)
Table 115. Asia-Pacific Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity by Application (2026-2031) & (K Units)
Table 116. Asia-Pacific Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity by Region (2020-2025) & (K Units)
Table 117. Asia-Pacific Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity by Region (2026-2031) & (K Units)
Table 118. Asia-Pacific Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value by Region (2020-2025) & (USD Million)
Table 119. Asia-Pacific Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value by Region (2026-2031) & (USD Million)
Table 120. South America Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity by Type (2020-2025) & (K Units)
Table 121. South America Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity by Type (2026-2031) & (K Units)
Table 122. South America Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity by Application (2020-2025) & (K Units)
Table 123. South America Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity by Application (2026-2031) & (K Units)
Table 124. South America Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity by Country (2020-2025) & (K Units)
Table 125. South America Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity by Country (2026-2031) & (K Units)
Table 126. South America Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value by Country (2020-2025) & (USD Million)
Table 127. South America Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value by Country (2026-2031) & (USD Million)
Table 128. Middle East & Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity by Type (2020-2025) & (K Units)
Table 129. Middle East & Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity by Type (2026-2031) & (K Units)
Table 130. Middle East & Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity by Application (2020-2025) & (K Units)
Table 131. Middle East & Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity by Application (2026-2031) & (K Units)
Table 132. Middle East & Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity by Country (2020-2025) & (K Units)
Table 133. Middle East & Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity by Country (2026-2031) & (K Units)
Table 134. Middle East & Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value by Country (2020-2025) & (USD Million)
Table 135. Middle East & Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value by Country (2026-2031) & (USD Million)
Table 136. Monoclonal Antibodies for Non-small Cell Lung Cancer Raw Material
Table 137. Key Manufacturers of Monoclonal Antibodies for Non-small Cell Lung Cancer Raw Materials
Table 138. Monoclonal Antibodies for Non-small Cell Lung Cancer Typical Distributors
Table 139. Monoclonal Antibodies for Non-small Cell Lung Cancer Typical Customers

List of Figures

Figure 1. Monoclonal Antibodies for Non-small Cell Lung Cancer Picture
Figure 2. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Type, (USD Million), 2020 & 2024 & 2031
Figure 3. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Type in 2024
Figure 4. 5 mg/mL Examples
Figure 5. 10 mg/mL Examples
Figure 6. 25 mg/mL Examples
Figure 7. 50 mg/mL Examples
Figure 8. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value by Application, (USD Million), 2020 & 2024 & 2031
Figure 9. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Application in 2024
Figure 10. Hospitals Examples
Figure 11. Clinic Examples
Figure 12. Others Examples
Figure 13. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value, (USD Million): 2020 & 2024 & 2031
Figure 14. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value and Forecast (2020-2031) & (USD Million)
Figure 15. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity (2020-2031) & (K Units)
Figure 16. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Price (2020-2031) & (US$/Unit)
Figure 17. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity Market Share by Manufacturer in 2024
Figure 18. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Manufacturer in 2024
Figure 19. Producer Shipments of Monoclonal Antibodies for Non-small Cell Lung Cancer by Manufacturer Sales ($MM) and Market Share (%): 2024
Figure 20. Top 3 Monoclonal Antibodies for Non-small Cell Lung Cancer Manufacturer (Revenue) Market Share in 2024
Figure 21. Top 6 Monoclonal Antibodies for Non-small Cell Lung Cancer Manufacturer (Revenue) Market Share in 2024
Figure 22. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity Market Share by Region (2020-2031)
Figure 23. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value Market Share by Region (2020-2031)
Figure 24. North America Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value (2020-2031) & (USD Million)
Figure 25. Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value (2020-2031) & (USD Million)
Figure 26. Asia-Pacific Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value (2020-2031) & (USD Million)
Figure 27. South America Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value (2020-2031) & (USD Million)
Figure 28. Middle East & Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value (2020-2031) & (USD Million)
Figure 29. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity Market Share by Type (2020-2031)
Figure 30. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value Market Share by Type (2020-2031)
Figure 31. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Average Price by Type (2020-2031) & (US$/Unit)
Figure 32. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity Market Share by Application (2020-2031)
Figure 33. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Application (2020-2031)
Figure 34. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Average Price by Application (2020-2031) & (US$/Unit)
Figure 35. North America Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity Market Share by Type (2020-2031)
Figure 36. North America Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity Market Share by Application (2020-2031)
Figure 37. North America Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity Market Share by Country (2020-2031)
Figure 38. North America Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value Market Share by Country (2020-2031)
Figure 39. United States Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value (2020-2031) & (USD Million)
Figure 40. Canada Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value (2020-2031) & (USD Million)
Figure 41. Mexico Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value (2020-2031) & (USD Million)
Figure 42. Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity Market Share by Type (2020-2031)
Figure 43. Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity Market Share by Application (2020-2031)
Figure 44. Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity Market Share by Country (2020-2031)
Figure 45. Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value Market Share by Country (2020-2031)
Figure 46. Germany Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value (2020-2031) & (USD Million)
Figure 47. France Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value (2020-2031) & (USD Million)
Figure 48. United Kingdom Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value (2020-2031) & (USD Million)
Figure 49. Russia Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value (2020-2031) & (USD Million)
Figure 50. Italy Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value (2020-2031) & (USD Million)
Figure 51. Asia-Pacific Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity Market Share by Type (2020-2031)
Figure 52. Asia-Pacific Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity Market Share by Application (2020-2031)
Figure 53. Asia-Pacific Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity Market Share by Region (2020-2031)
Figure 54. Asia-Pacific Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value Market Share by Region (2020-2031)
Figure 55. China Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value (2020-2031) & (USD Million)
Figure 56. Japan Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value (2020-2031) & (USD Million)
Figure 57. South Korea Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value (2020-2031) & (USD Million)
Figure 58. India Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value (2020-2031) & (USD Million)
Figure 59. Southeast Asia Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value (2020-2031) & (USD Million)
Figure 60. Australia Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value (2020-2031) & (USD Million)
Figure 61. South America Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity Market Share by Type (2020-2031)
Figure 62. South America Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity Market Share by Application (2020-2031)
Figure 63. South America Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity Market Share by Country (2020-2031)
Figure 64. South America Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value Market Share by Country (2020-2031)
Figure 65. Brazil Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value (2020-2031) & (USD Million)
Figure 66. Argentina Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value (2020-2031) & (USD Million)
Figure 67. Middle East & Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity Market Share by Type (2020-2031)
Figure 68. Middle East & Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity Market Share by Application (2020-2031)
Figure 69. Middle East & Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity Market Share by Country (2020-2031)
Figure 70. Middle East & Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value Market Share by Country (2020-2031)
Figure 71. Turkey Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value (2020-2031) & (USD Million)
Figure 72. Egypt Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value (2020-2031) & (USD Million)
Figure 73. Saudi Arabia Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value (2020-2031) & (USD Million)
Figure 74. South Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value (2020-2031) & (USD Million)
Figure 75. Monoclonal Antibodies for Non-small Cell Lung Cancer Market Drivers
Figure 76. Monoclonal Antibodies for Non-small Cell Lung Cancer Market Restraints
Figure 77. Monoclonal Antibodies for Non-small Cell Lung Cancer Market Trends
Figure 78. Porters Five Forces Analysis
Figure 79. Manufacturing Cost Structure Analysis of Monoclonal Antibodies for Non-small Cell Lung Cancer in 2024
Figure 80. Manufacturing Process Analysis of Monoclonal Antibodies for Non-small Cell Lung Cancer
Figure 81. Monoclonal Antibodies for Non-small Cell Lung Cancer Industrial Chain
Figure 82. Sales Channel: Direct to End-User vs Distributors
Figure 83. Direct Channel Pros & Cons
Figure 84. Indirect Channel Pros & Cons
Figure 85. Methodology
Figure 86. Research Process and Data Source